Oxaliplatin is a platinum-based antineoplastic chemotherapy drug used mainly for colorectal cancer, often in combination regimens such as FOLFOX or CAPOX. It is administered intravenously and marketed under the trade name Eloxatin. European approval occurred in 1996 and U.S. FDA approval followed in 2002.
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
Epcoritamab plus lenalidomide cut progression risk by 60% in R/R DLBCL in a phase 3 trial. Five-year AUGMENT follow-up supports R2 in indolent NHL; a phase 2 penpulimab-lenalidomide-R-GemOx trial showed activity in DLBCL.
A Phase 1b/2 trial in 28 patients found nivolumab plus modified FOLFIRINOX was well tolerated before surgery in borderline-resectable pancreatic cancer. Seventy-nine percent proceeded to surgery, with complete tumor removal in all resected patients.
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.
Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07776639 |
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction |
RECRUITING | PHASE2 |
| NCT07775287 |
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07774234 |
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07748611 |
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07737600 |
A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07733180 |
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07730021 |
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07727993 |
Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07716449 |
QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ |
NOT_YET_RECRUITING | PHASE3 |
| NCT07709767 |
Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma |
NOT_YET_RECRUITING | PHASE2 |
